The direct oral anticoagulants (DOACs), which include dabigatran, rivaroxaban, apixaban,
and edoxaban, are licensed for stroke prevention in patients with atrial fibrillation and for …

Bleeding is the main adverse effect when using oral anticoagulants (OACs). The risk of
major bleeding with vitamin K antagonists (VKAs) is dependent on the quality of …

Idarucizumab, a Fab fragment directed against dabigatran, produced rapid and complete
reversal of the anticoagulation effect of dabigatran in animals and in healthy volunteers. The …

Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used in the
prevention and treatment of venous thromboembolism and in the prevention of stroke in …

Although there is controversy about the absolute need for a reversal agent for the new direct
oral anticoagulants (DOACs), the absence of such an agent is a barrier to more widespread …

An increasing number of individuals are on novel oral anticoagulants (NOAC) for
anticoagulation instead of vitamin K antagonists (VKA) and roughly 10% of these individuals …

The non-vitamin K antagonist oral anticoagulants (NOACs) are used for thromboembolic
prophylaxis of patients with atrial fibrillation and in the treatment as well as secondary …

Nonvalvular atrial fibrillation‐(NVAF‐) related stroke and venous thromboembolism (VTE)
are cardiovascular diseases associated with significant morbidity and economic burden. The …

Atrial fibrillation (AF) is a common heart rhythm disturbance; its incidence increases with
age, and it is also an independent risk factor for stroke. Anticoagulation has been proven as …

The vitamin K antagonists (VKAs) have been the standard (and only) oral anticoagulants
used for the long-term treatment or prevention of venous thromboembolism or stroke in …